MX2013012918A - Formulaciones de liberacion sostenida de paracetamol. - Google Patents

Formulaciones de liberacion sostenida de paracetamol.

Info

Publication number
MX2013012918A
MX2013012918A MX2013012918A MX2013012918A MX2013012918A MX 2013012918 A MX2013012918 A MX 2013012918A MX 2013012918 A MX2013012918 A MX 2013012918A MX 2013012918 A MX2013012918 A MX 2013012918A MX 2013012918 A MX2013012918 A MX 2013012918A
Authority
MX
Mexico
Prior art keywords
sustained release
paracetamol
release paracetamol
paracetamol formulations
release phase
Prior art date
Application number
MX2013012918A
Other languages
English (en)
Inventor
Kanji Meghpara
Carla Valenti Buan
Dongzhou Liu
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2013012918A publication Critical patent/MX2013012918A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presente está dirigida a una composición farmacéutica de liberación sostenida de dos veces al día de paracetamol que tiene una fase de liberación inmediata de paracetamol y una fase de liberación sostenida de paracetamol, dicha composición tiene propiedades farmacocinéticas únicas y ventajosas y una composición farmacéutica que comprende sólo una fase de liberación sostenida de paracetamol que tiene propiedades farmacocinéticas únicas y ventajosas.
MX2013012918A 2011-05-06 2012-05-04 Formulaciones de liberacion sostenida de paracetamol. MX2013012918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161483320P 2011-05-06 2011-05-06
PCT/US2012/036528 WO2012154563A1 (en) 2011-05-06 2012-05-04 Sustained release paracetamol formulations

Publications (1)

Publication Number Publication Date
MX2013012918A true MX2013012918A (es) 2013-11-21

Family

ID=47139543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012918A MX2013012918A (es) 2011-05-06 2012-05-04 Formulaciones de liberacion sostenida de paracetamol.

Country Status (19)

Country Link
US (1) US20140065213A1 (es)
EP (1) EP2704697B1 (es)
CN (1) CN103648486A (es)
AP (1) AP3878A (es)
AU (1) AU2012253834B2 (es)
BR (1) BR112013028668A2 (es)
CA (1) CA2835330A1 (es)
CL (1) CL2013003176A1 (es)
CO (1) CO6801767A2 (es)
CR (1) CR20130572A (es)
DO (1) DOP2013000258A (es)
EA (1) EA201391643A1 (es)
GT (1) GT201300270A (es)
MX (1) MX2013012918A (es)
NI (1) NI201300116A (es)
SG (1) SG194605A1 (es)
TW (1) TW201306881A (es)
WO (1) WO2012154563A1 (es)
ZA (1) ZA201308316B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TW201507726A (zh) * 2013-05-10 2015-03-01 Glaxosmithkline Llc 菸鹼菱形錠配製物
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
PL3265126T3 (pl) 2015-03-03 2021-12-06 Saniona A/S Preparaty połączenia tesofensyny i metoprololu
BE1023116B1 (nl) * 2015-07-24 2016-11-23 Nordic Specialty Pharma Bvba Paracetamol omvattend preparaat met vertraagde en aanhoudende afgifte

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN940796A0 (en) * 1996-04-23 1996-05-16 F.H. Faulding & Co. Limited Taste masked pharmaceutical compositions
EP1017370B1 (en) * 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
CA2491355A1 (en) * 2002-07-05 2004-01-15 Temrel Limited Controlled release compositions comprising coated pellets having non-uniform coating thicknesses
MXPA06003454A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada de analgesicos opioides y no opiodes.
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
PL1781277T3 (pl) * 2004-07-07 2012-07-31 Aft Pharmaceuticals Ltd Kompozycja łączona zawierająca ibuprofen i paracetamol
MX2010008420A (es) * 2008-02-01 2012-09-19 Abbott Lab Hidrocodona acetaminofen de liberacion extendida y metodos relacionados y sus usos.
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
US8021420B2 (en) * 2009-03-12 2011-09-20 Medtronic Vascular, Inc. Prosthetic valve delivery system
EP2473195A4 (en) * 2009-08-31 2013-01-16 Depomed Inc PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES

Also Published As

Publication number Publication date
ZA201308316B (en) 2014-07-30
NI201300116A (es) 2014-11-13
CN103648486A (zh) 2014-03-19
WO2012154563A1 (en) 2012-11-15
TW201306881A (zh) 2013-02-16
DOP2013000258A (es) 2014-07-15
NZ617198A (en) 2016-01-29
EP2704697B1 (en) 2018-09-12
AP2013007224A0 (en) 2013-11-30
AU2012253834A1 (en) 2013-12-05
EP2704697A1 (en) 2014-03-12
CR20130572A (es) 2014-03-20
US20140065213A1 (en) 2014-03-06
EP2704697A4 (en) 2015-01-07
AP3878A (en) 2016-10-31
CO6801767A2 (es) 2013-11-29
CL2013003176A1 (es) 2014-07-04
EA201391643A1 (ru) 2014-07-30
GT201300270A (es) 2014-12-16
CA2835330A1 (en) 2012-11-15
AU2012253834B2 (en) 2016-06-16
SG194605A1 (en) 2013-12-30
BR112013028668A2 (pt) 2017-01-24

Similar Documents

Publication Publication Date Title
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
IL247804B (en) Heterocyclic modulators of lipid synthesis, preparations containing them and their uses
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2013005974A (es) Formulacion de lacosamida de administracion una vez al dia.
MY181898A (en) Heterocyclic compounds and uses thereof
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
MX2013001677A (es) Formulaciones estables de linaclotida.
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2013012918A (es) Formulaciones de liberacion sostenida de paracetamol.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
PH12014501840A1 (en) Pharmaceutical formulation having improved stability
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
MX2011011180A (es) Compuestos que tienen efecto fisiologico.
IN2015DN02660A (es)
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
IN2013MU01944A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal